A previous study has illustrated that the blockade of IL-6 with tocilizumab, approved by the Food and Drug Administration for treatment of rheumatoid arthritis, could attenuate the self-renewal of CD44+ liver CSCs and decrease tumorigenesis, suggesting its potential to target liver CSCs and application in the clinical management of HCC patients [27]. This evidence concerns the gene CD44 and hepatocellular carcinoma.